CVRx Inc: Overreaction Creates Buying Opportunity
Source: SeekingAlpha
2025-04-09 08:45:06 ET
Summary
- CVRx Inc. stock has recently dropped 40%, presenting a buying opportunity as the long-term growth potential remains intact.
- Barostim has strong clinical results and significant market potential, with a $2.2 billion TAM.
- Average selling prices can potentially improve as the market recognizes Barostim's effectiveness.
- CVRX shares are a buy with price target of $10.
Thesis Recap
Read the full article on Seeking Alpha
For further details see:
CVRx Inc: Overreaction Creates Buying Opportunity
CVRx Inc.
NASDAQ: CVRX
CVRX Trading
1.13% G/L:
$7.58 Last:
74,533 Volume:
$7.39 Open:
CVRX Latest News
March 02, 2026 08:30:00 am
CVRx Announces Late-Breaking Data and Scientific Presentations Highlighting Barostim Outcomes at the THT 2026 Annual Meeting
February 12, 2026 04:05:00 pm
CVRx Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
CVRX Stock Data
$174,952,478
20,522,515
15.36%
28
N/A
Medical Equipment & Supplies
Healthcare
US
Minneapolis
